Objective-Several secreted phospholipases A2 (sPLA2s), including group IIA, III, V, and X, have been linked to the development of atherosclerosis, which led to the clinical testing of A-002 (varespladib), a broad sPLA2 inhibitor for the treatment of coronary artery disease. Group X sPLA2 (PLA2G10) has the most potent hydrolyzing activity toward phosphatidylcholine and is believed to play a proatherogenic role. Methods and Results-Here, we show that Ldlr -/mice reconstituted with bone marrow from mouse group X-deficient mice (Pla2g10 -/-) unexpectedly display a doubling of plaque size compared with Pla2g10 +/+ chimeric mice. Macrophages of Pla2g10 -/mice are more susceptible to apoptosis in vitro, which is associated with a 4-fold increase of plaque necrotic core in vivo. In addition, chimeric Pla2g10 -/mice show exaggerated T lymphocyte (Th)1 immune response, associated with enhanced T-cell infiltration in atherosclerotic plaques. Interestingly, overexpression of human PLA2G10 in murine bone marrow cells leads to significant reduction of Th1 response and to 50% reduction of lesion size.
S ecreted phospholipases A 2 (sPLA2s) form a structurally conserved family of enzymes that catalyze the hydrolysis of glycerophospholipids at the sn-2 position, leading to the production of free fatty acids and lysophospholipids. 1 There is now accumulating evidence that several sPLA2 isoforms, namely group IIA (GIIA), GIII, GV, and GX play significant, distinct, or overlapping roles in one or several steps of atherogenesis. [2] [3] [4] [5] [6] [7] [8] [9] The sPLA2s exert multiple proatherogenic effects in the arterial wall by generating proinflammatory bioactive lipid mediators, by hydrolyzing low-density lipoprotein (LDL) and generating proatherogenic LDL particles, and by activating different inflammatory cells through catalytically dependent and independent mechanisms. There is also ample epidemiological evidence on the association between increased GIIA mass or sPLA2 activity (which potentially reflects all sPLA2 isoforms) and risk of cardiovascular disease. 8, 10, 11 GIIA, GIII, GV, and GX sPLA2s have been detected in human and mouse atherosclerotic lesions. 6, [12] [13] [14] Genetically modified mice (knockout and transgenic) also provided evidence that GIIA, GIII, and GV are proatherogenic. 6, 15, 16 Moreover, treatment of animals with varespladib, a broadly specific inhibitor of various sPLA2 isoforms, reduces atherosclerosis development and aneurysm formation, 17, 18 and clinical trials have been initiated to test the efficacy of this sPLA2 inhibitor in patients with coronary artery disease. 19, 20 GX sPLA2 (PLA2G10) is distantly structurally related to other sPLA2 isoforms and is the most potent enzyme at hydrolyzing phosphatidylcholine, the most abundant phospholipid at the cell surface and on lipoproteins. 21, 22 Gene targeting of Pla2g10 modulates lung inflammation in a mouse model of asthma 23, 24 and attenuates neutrophil activity in ischemic myocardium, 25 suggesting that PLA2G10 is implicated in the modulation of innate and adaptive immune responses and may represent a novel therapeutic target for the treatment of cardiovascular diseases. 26 PLA2G10 is expressed in peripheral blood leukocytes, neutrophils, and macrophages, and has been detected within atherosclerotic lesions. 27, 28 PLA2G10 may promote foam cell formation by enhancing the atherogenic properties of LDL particles 3, 12 and by reducing cholesterol efflux. 29 It may also promote toll-like receptor4 signaling in macrophages 30 and has been suggested to promote dendritic cell (DC) maturation in vitro through the modification of LDL. 31 However, its in vivo role in models of atherosclerosis is still poorly explored. In this study, we investigated the role of PLA2G10 in the development of atherosclerosis and focused on bone marrow-derived PLA2G10 using an LDL receptor-deficient (Ldlr -/-) chimeric mouse model.
Materials and Methods
Detailed description of the methodology can be found in the onlineonly Data Supplement.
Animals
Pla2g10 -/mice (null for the Pla2g10 gene) were obtained from Lexicon Inc and were backcrossed for more than 10 generations into a C57BL/6J background. Transgenic (Tg) human PLA2G10 mice were previously described and were on a C57BL/6 background. 32 Twelveweek-old male C57BL/6 Ldlr -/mice (Jackson Laboratory) were subjected to medullar aplasia, and were reconstituted with bone marrow cells isolated from sex-matched Pla2g10 -/mice or Pla2g10 +/+ littermates. In other experiments, irradiated Ldlr -/mice were reconstituted with Tg-hPLA2G10 or control littermate bone marrow. After 4 weeks of recovery, mice were fed a proatherogenic diet containing 15% fat, 1.25% cholesterol, and 0% cholate for 8 weeks.
Extent and Composition of Atherosclerotic Lesions
Lipoprotein profile was assessed using fast protein liquid chromatography. Lipids and collagen accumulation in the intima were detected using Oil Red O and Sirius red staining, respectively. The presence of T-cells, macrophages, and smooth muscle cells was studied using specific antibodies, as previously described. 33 PLA2G10 was detected in lesions using a rabbit polyclonal antibody. 34 TUNEL staining was performed using in situ Cell Death Detection Kit (Roche). At least 4 sections per mouse were examined for each immunostaining, and appropriate negative controls were used.
Spleen Cell Recovery and Cytokine Assays
Spleen cells were purified according to standard protocols using antibody-coated magnetic beads from Miltenyi Biotech. For cytokine measurements, splenocytes were stimulated with lipopolysaccharide (10 μg/mL) and interferon (IFN)-γ (100 UI/mL) for 24 or 48 hours. CD4 + T-cells were cultured at 1×10 5 cells/well for 48 hours in anti-CD3-coated microplates (10 μg/mL). Interleukin (IL)-4, IL-10, IL-12, and IFN-γ productions in the supernatants were measured using specific ELISAs (R&D Systems).
Cell Culture and Proliferation Assays
To analyze T-cell proliferation, 1×10 5 CD4 + cells/well were cocultured with 10 4 CD11c + DCs and soluble anti-CD3 (1ug/mL) for 72 hours. One μCi [ 3 H] thymidine was added to each well during the last 16 hours.
Regulatory T-cell function was assayed, as previously described. 35 
Flow Cytometry
Details of antibodies used are given in the Methods in the online-only Data Supplement.
Macrophage Apoptosis
To analyze apoptosis susceptibility, macrophages were incubated with tumor necrosis factor-α (10 ng/mL) and cycloheximide (10 μmol/L) for 6 hours, etoposide (50 μmol/L), C2-ceramide (50 μmol/L), or staurosporine (100 nmol/L) for 12 hours. Macrophages were fixed in 4% paraformaldehyde and DNA was stained with 4′,6-diamidino-2-phenylindole (Calbiochem). Nuclear morphology was examined by fluorescence microscopy or using flow cytometry (see the Methods in the online-only Data Supplement).
Phagocytosis Studies
In vitro, bone marrow-derived macrophages were coincubated with apoptotic (dexamethasone-treated) carboxyfluorescein succinimidyl ester (CFSE)-labeled thymocytes (10×10 6 cells) for 1 hour. Phagocytosis was measured as the percentage of CFSE cells among CD11b/F4/80-positive cells.
In vivo, Pla2g10 +/+ (n=5) and Pla2g10 -/-(n=6) mice received an intraperitoneal injection of apoptotic (dexamethasone-treated) CFSE labeled thymocytes (20×10 6 ) or saline 3 days after thioglycollate (3%, 2 mL) injection. Phagocytosis was allowed to proceed for 1 hour, and macrophages were recovered and analyzed by flow cytometry, after staining with CD11b and F4/80.
Antibodies Measurements
These measurements were performed, as previously described. 36 
Quantitative Polymerase Chain Reaction
Total RNA was extracted from bone marrow, spleen, and aorta using TRIzol reagent (Invitrogen). RNA was first treated with DNase I (Invitrogen) then reverse transcribed using Moloney Murine Leukemia Virus reverse transcriptase (Promega). Quantitative PCR was performed using a LightCycler 480 Real-Time PCR System (Roche Applied Science) and qPCR Master Mix Plus SYBR Green (Eurogentec). The abundance of hPLA2G10 mRNA was expressed relative to the expression of the housekeeping gene glyceraldehyde-3-phosphate dehydrogenase mRNA (Gapdh).
Time-Resolved Fluorescence Immunoassay
Bone marrow cell lysates from Tg-hPLA210 or wild-type C57BL/6J mice were prepared. Time-resolved fluorescence immunoassay (TR-FIA) analysis was performed, as previously described. 37 TR-FIA was measured using a Wallac Envision PerkinElmer plate reader and optimized optical modules for assays.
sPLA2 Enzymatic Activity
The sPLA2 enzymatic activity was measured using radiolabeled Escherichia coli membranes as substrate (see the Methods in the online-only Data Supplement). Human PLA2G10-specific inhibitor (inhibitor B, RO 092906A, 1 μmol/L) or antihPLA2G10 antibody (IgG fraction, 3 μg) 24 were preincubated with cell lysates for 15 minutes before incubation with the radioactive substrate.
Statistical Analysis
Values are expressed as means±SEM. Differences between values were examined using the 2-tailed Student t test, and were considered significant at P<0.05.
Results
We performed bone marrow transplantation experiments using either Pla2g10 +/+ or Pla2g10 -/bone marrow to repopulate lethally irradiated Ldlr -/mice. As shown in Figure 1A after 8 weeks on high-fat diet, PLA2G10 expression in atherosclerotic lesions was confined to intimal bone marrow-derived cells and was barely detectable in lesions of mice reconstituted with Pla2g10 -/bone marrow. Pla2g10 deficiency in bone marrow did not alter lesion size in the thoracic aorta ( Figure I in the online-only Data Supplement), but was associated with more than 2-fold increase in lesion development in the aortic sinus compared with controls. Because this result was unexpected, we repeated the experiment with a new set of mice. Again, Pla2g10 deficiency led to increased development of atherosclerosis in the aortic sinus. Pooled results from the 2 separate experiments are shown in Figure 1B and indicate a marked acceleration of atherosclerosis in the Pla2g10 -/-→ Ldlr -/group (lesion size, 294, 254±89, 628 μm 2 versus 142, 304±140, 541 μm 2 , in Pla2g10 -/-→ Ldlr −/− and Pla2g10 +/+ → Ldlr -/-, respectively; P=0.001). We observed no differences in body weight, serum cholesterol level, or serum lipoprotein profile between the 2 groups of mice ( Figure II in the online-only Data Supplement).
To gain insight into the mechanisms of lesion acceleration in Pla2g10 -/-→ Ldlr -/mice, we analyzed lesion composition. We found an increase of collagen accumulation (9.7±6.0% versus 3.1±2.8%; P=0.04) and a decrease of relative macrophage content in plaques of chimeric Pla2g10 -/mice (mean percentage area occupied by CD68+ cells, 24.8±7.2% versus 33.1±8.1%, in Pla2g10 -/-→ Ldlr -/and Pla2g10 +/+ → Ldlr -/mice, respectively; P=0.05; Figure 1C and 1D). Although these features might suggest enhanced plaque stability, they could simply reflect a more advanced stage of lesion development in the chimeric Pla2g10 -/animals. In fact, we found enhanced accumulation of TUNEL-positive cells (Figure 2A ) and a 4-fold increase of necrotic core size in atherosclerotic plaques of Pla2g10 -/-→ Ldlr -/mice compared with controls ( Figure  2B ). In general, an increase of apoptotic cells and debris during lesion progression is attributed to defective efferocytosis. [38] [39] [40] However, we observed no alteration of efferocytosis by Pla2g10 -/macrophages neither in vitro nor in vivo ( Figure  2C ). The vast majority of TUNEL-positive cells accumulated in the lipid core of the lesion, a macrophage-rich area, suggesting that these apoptotic cells were of macrophage origin. This is in agreement with our in situ costaining data (not shown) and the in vitro data showing that Pla2g10 -/macrophages are more susceptible to apoptotic stimuli ( Figure 2D and Figure III in the online-only Data Supplement).
We then looked at T-cell infiltration within the lesions. We found a marked increase in T-cell numbers in lesions of Pla2g10 -/-→ Ldlr -/compared with Pla2g10 +/+ → Ldlr -/mice ( Figure 3A ). We therefore looked at the immunoinflammatory response in the spleen. Interestingly, splenic CD4 + T-cells purified from Pla2g10 -/mice showed an enhanced proliferative response in culture ( Figure 3B ) and an exaggerated Th1 phenotype ( Figure 3C and 3D and Figure IV in the online-only Data Supplement), which was independent of the DC phenotype ( Figure V in the online-only Data Supplement). Ex vivo flow cytometry analysis showed a 35% increase of IFN-γ + CD4 + T-cells among the CD4 + population (P<0.05; Figure 3D ), with no difference for IL-10 (data not shown). Intracellular IL-4 was not detected. We also confirmed a more than 3-fold increase of IFN-γ production in the supernatants of anti-CD3-stimulated CD4 + T-cells from Pla2g10 -/-→ Ldlr -/mice compared with Pla2g10 +/+ → Ldlr -/mice ( Figure 3C ). IL-10 and IL-4 productions were not different between groups ( Figure 3C ). Interestingly enough, enhanced IFN-γ production was associated with increased accumulation of major histocompatibility complex-II-positive cells within the lesions of chimeric Pla2g10 -/compared with controls ( Figure 3E ), suggesting an enhanced local Th1-related adaptive immune response.
We then examined whether the exaggerated proinflammatory Th1 profile in Pla2g10 -/mice could be a result of alteration of regulatory T-cell population that failed to suppress pathogenic T-cells. However, we detected the same proportion of natural regulatory T-cells (CD4 + CD25 high Foxp3 + cells among CD4 + T-cells) in Pla2g10 -/and Pla2g10 +/+ mice (the online-only Data Supplemental Figure VI) . Also, purified regulatory T-cells isolated from both groups were cocultured with effector T-cells and displayed similar suppressive functions ( Figure VI in the online-only Data Supplement), suggesting no specific alteration in regulatory T-cell response.
Finally, we addressed the effects of transgenic overexpression of hPLA2G10 in bone marrow-derived cells on the immune response of atherosclerosis using the same bone marrow transplantation strategy in Ldlr -/mice. Using quantitative PCR, we found that hPLA2G10 was expressed in bone marrow of Tg-hPLA2G10 mice and detected in spleen and atherosclerotic lesions of mice reconstituted with hPLA2G10 bone marrow ( Figure VII in the online-only Data Supplement). We also detected protein levels of hPLA2G10 in extracts of bone marrow cells using TR-FIA immunoassay, which was associated with the detection of a specific enzymatic activity ( Figure   VII in the online-only Data Supplement). In line with the above-described role of mouse PLA2G10 on Th1 immunity, hPLA2G10 overexpression in mice limited IFN-γ production by T-cells ( Figure VIII in the online-only Data Supplement). Remarkably, we found that after 8 weeks on high-fat diet, PLA2G10 overexpression was associated with a 50% reduction of lesion development in the aortic sinus compared with controls ( Figure 4A ), despite no difference in body weight (25.6±3.3 g versus 26.6±1.9 g; P=0.54) or plasma cholesterol levels (13.2±2.2 g/L versus 11.2±2.2 g/L; P=0.08). This was associated with a marked reduction of Th1 responses, including the production of IFN-γ ( Figure 4D ), IL-12p70 ( Figure 4E) , and tumor necrosis factor α ( Figure 4F) , with concomitant increase in the antiinflammatory cytokine IL-10 ( Figure 4G ), indicating an antiatherogenic immune response. Reduced Th1-dependent immunity was further associated with a selective reduction of Th1-related IgG2c type antimalondialdehyde-LDL (P=0.02; Figure 4H ) and anti-CuOx-LDL antibodies (P=0.006; Figure 4I ) but preservation of IgG1 and IgM type antibodies ( Figure 4H and 4I) . 
Discussion
In vitro data suggested that PLA2G10 plays a pathogenic role in atherosclerosis mainly through promotion of macrophage foam cell formation. 3, 12, 29 However, we now present evidence that in vivo, the dominant effect of PLA2G10 is rather antiatherosclerotic and relates to the control of the adaptive immune response. C57BL/6 mice show a predominant Th1 response in the context of atherosclerosis. 41 Collectively, our data indicate that expression of GX sPLA2 restrains Th1 activation, thereby limiting the development of atherosclerosis. 42 The exaggerated Th1 response in Pla2g10 -/mice compared with wild-type animals was not dependent on differences in DC maturation. In fact, DCs do not express Pla2g10. 31 Our results are in agreement with those from Henderson et al 23 showing a significant reduction of Th2 responses in Pla2g10 -/on a mixed 129sv/C57BL/6J background in the context of asthma, and are in line with data from Curfs et al 7 reporting that overexpression of PLA2G10 in macrophages induced an antiinflammatory phenotype, with increased production of IL-10 and decreased production of tumor necrosis factor α in culture.
The reduction of atherosclerosis was confined to the aortic sinus. There are several potential explanations for this finding. The most plausible explanation relates to the site-specific effect of lymphocytes, in general, and Th1 cells, in particular, in the context of experimental atherogenesis. It is interesting to note that both T-bet and Ifnγ deficiencies lead to larger reduction in lesion size in the aortic root compared with descending aorta 43, 44 during the first 8 weeks of high-fat diet. It is not until 20 weeks of high-fat diet that the effect of Th1 deficiency becomes more apparent in the descending aorta. 43 In addition, Reardon et al 45 have nicely shown that lymphocyte deficiency reduces lesion development in the aortic sinus but had no effect on lesion development in the innominate artery in fully backcrossed C57BL/6 mice, which is in agreement with our present findings.
It should be noted that Zack et al 46 recently reported that Pla2g10 deficiency may be associated with reduced development of atherosclerosis. This reduction was only observed in the aortic arch, and no difference of lesion size was detected at the aortic sinus. Several factors might account for the differences between the previous results and ours. They studied Pla2g10 deficiency on an Apoe -/background, whereas we used the Ldlr -/background. LDL particles from Apoe -/and Ldlr -/may show differential susceptibility to modifications by sPLA2 isoforms. 5 They studied a much earlier stage of lesion development than we did in the present study. In addition, their assessment of lesion size was performed only under angiotensin II infusion, which might have confounded results interpretation. Finally, we have addressed the role of Pla2g10 deficiency in bone marrow-derived cells, whereas Pla2g10 deficiency was total in the study by Zack et al. 46 However, as shown in Figure 1A of this study, PLA2G10 expression in lesions colocalizes with bone marrow-derived nonvascular cells. Thus, the contribution of vascular-derived PLA2G10 to atherosclerosis is probably minimal. Importantly, we show that overexpression of hPLA2G10 in mice leads to reduction of adaptive Th1 immunity in association with an antiinflammatory response and an antiatherogenic phenotype. The results are clearly in favor of an atheroprotective role of PLA2G10, at least in part, through limitation of pathogenic immune responses. Additional PLA2G10-related atheroprotective effects may involve reduced susceptibility of macrophages to apoptosis, thereby limiting the formation of a secondary necrotic lipid core and preventing additional activation of the immunoinflammatory response by late apoptotic and secondary necrotic material. [38] [39] [40] Further studies will be necessary to delineate the mechanisms by which PLA2G10 activity alters innate and adaptive immune responses, and to address the role of PLA2G10 in the progression of advanced lesions.
In summary, our results clearly show that Pla2g10 deficiency in bone marrow-derived cells accelerates the development of atherosclerosis in the aortic sinus of Ldlr -/mice, most likely through an exaggerated Th1 immunoinflammatory response. We also observed that Pla2g10 deficiency induced an increase of necrotic core size, with enhanced accumulation of apoptotic macrophages within the lesions. In line with these results, overexpression of hPLA2G10 in bone marrow cells limits Th1 responses and lesion development. The data provide robust evidence for a novel antiinflammatory role of GX sPLA2 in atherosclerosis and are in direct opposition with the reported proatherogenic roles, yet via distinct mechanisms, of other sPLA2 isoforms, including GIIA, 15, 47 GV, 16 or GIII 6 sPLA2s. How these sPLA2 isoforms exert such specific and opposite roles in atherosclerosis at the molecular level remains to be determined, but likely relies with their tissue and cell-specific expression, and their highly specific enzymatic properties on cells and lipoproteins. 22, 48, 49 Recently, a clinical trial testing the efficacy of A-002/varespladib, 20 a broadly specific inhibitor of sPLA2s GIIA, GV, and GX, 17 in patients with coronary artery disease was stopped for futility. 50 Our results may provide, at least in part, an explanation for the lack of efficacy of this inhibitor and clearly highlight the need for a specific targeting of individual sPLA2 enzymes with highly selective inhibitors that can discriminate between isoforms. The use of such highly specific inhibitors may lead to more effective treatment of atherosclerosis.
